Drug product production, clinical support studies, and phase 1 trial of a new MS drug

我们发明了一种新的、一流的治疗多发性硬化症(MS)的药物。这种药物有可能成为治疗多发性硬化症肌肉痉挛的标准药物，与目前的药物相比，患者的副作用更少、更轻。特别是，更早的治疗应该是可以实现的，以对抗残疾的发作，并允许正常生命维持更长的时间。TSB的资金将使这种药物的第一次临床研究成为可能。部分资金已经从Wellcome Trust和UCL业务中获得。第一名志愿者预计将于2013年第三季度/第四季度开始服药。

We have invented a new, first in class, drug for the treatment of multiple sclerosis (MS). This drug has the potential to become the standard of care for the treatment of muscle spasticity in MS with fewer and less severe side effects for patients than current drugs. In particular earlier treatment should be achievable, countering the onset of disability and allowing a normal life to be sustained for longer.TSB funding will enable the first clinical studies for this drug. Part funding has already been secured from the Wellcome Trust, and UCL business. The first volunteer is expected to be dosed in Q3/Q4 2013.